TRIPLE G 20 mg PEN

One-Peptides TRIPLE G 20 mg PEN – GLP-1/GIP/glucagon tri-agonist in a pen format

Triple G 20 mg PEN is a research reagent (Research Use Only) supplied as a pre-dissolved pen. The pen is only the physical format of the reagent. It may resemble pharmaceutical GLP-1 pens, but no incretin-receptor tri-agonist is registered as a medicine in the EU or the USA.

Retatrutide (LY3437943, Eli Lilly), the best clinically characterized tri-agonist related to the Triple G class, remains in the phase III TRIUMPH clinical program, without marketing authorization. Triple G PEN in the One Peptides catalog functions in a separate regulatory frame as a laboratory research chemical, not as a therapeutic product.

Do not confuse Triple G with approved medicines: semaglutide (Ozempic, Wegovy) is a GLP-1 mono-agonist, while tirzepatide (Mounjaro, Zepbound) is a GLP-1/GIP dual-agonist. Tri-agonists are not included among approved drug classes. Label: For research use only. Not for human use.

In July 2023, The New England Journal of Medicine published phase 2 data on retatrutide (LY3437943), an Eli Lilly incretin-receptor tri-agonist that reported a 24.2% body-weight reduction after 48 weeks at the highest tested dose in adults with obesity (Jastreboff et al., 2023). The evolutionary step after dual-agonists such as tirzepatide is the third receptor: adding glucagon receptor (GCGR) activity to the GLP-1R + GIPR combination. A broader physiological background is available in the article on GLP-1, GIP and glucagon incretins.

Triple G is a research peptide from the class of incretin tri-agonists – molecules designed to activate three metabolic-axis receptors at the same time, structurally and mechanistically related to retatrutide.

Triple G 20 mg PEN is a separate physical format in the One Peptides catalog: an RUO reagent in a pre-dissolved pen, ready for sampling without lyophilizate reconstitution. Compared with a 10 mg lyophilized vial format, the pen provides a higher nominal peptide content and simpler handling while maintaining the same analytical quality standard: HPLC >=98%, MS identity confirmation and batch-specific COA. All reference findings come from experimental and clinical literature on related tri-agonist molecules, especially retatrutide. For the broader class context, see the guide to GLP-1 peptides in metabolic research.

What is Triple G 20 mg – pharmacological class

Triple G belongs to the class of incretin-receptor tri-agonists, a third generation of metabolic peptide pharmacology after mono-agonists such as semaglutide and dual-agonists such as tirzepatide. The molecule is intended to activate three G-protein-coupled receptors: GLP-1R, GIPR and GCGR.

The informal shorthand used for retatrutide in online searches is explained in a separate entry: an explanation of the term “reta”.

Its structural and mechanistic reference point is retatrutide (LY3437943), the most clinically advanced peptide in this class, first described by Coskun et al. (2022) in Cell Metabolism.

The compound is produced by solid-phase peptide synthesis (SPPS), followed by HPLC purification. Modern incretin analogs commonly include structural modifications such as fatty-acid acylation, which enables reversible albumin binding and extends serum half-life. In clinical retatrutide protocols, this supports once-weekly dosing schedules.

Chemical characteristics

The exact sequence of a catalog research peptide depends on the specific batch and is documented in the certificate of analysis (COA) issued for each lot.

Mechanism of action of Triple G 20 mg – why triple activation?

The tri-agonist concept comes from the observation that three incretin-axis hormones act at different levels of energy metabolism. Their simultaneous pharmacological activation can produce a synergistic effect that is not achievable with single-receptor targeting. Each pathway contributes differently.

GLP-1R (glucagon-like peptide-1 receptor). Activation increases glucose-dependent insulin secretion, suppresses postprandial glucagon secretion, slows gastric emptying and reduces appetite through central effects in the hypothalamus. This is the same receptor axis that underlies semaglutide pharmacology.

GIPR (glucose-dependent insulinotropic polypeptide receptor). Adding GIPR agonism strengthens the incretin effect, supporting insulin secretion during glucose load and modulating adipose-tissue metabolism. In preclinical models, GIP activity has also been discussed in the context of gastrointestinal tolerability. Tirzepatide is based on the GLP-1R + GIPR combination.

GCGR (glucagon receptor). This is the newer evolutionary element. In classical endocrinology, glucagon is associated with hepatic glucose mobilization, which seems contradictory in diabetes pharmacology. In tri-agonist pharmacology, GCGR agonism has another role: it may increase energy expenditure, induce thermogenic pathways and intensify lipolysis in liver and adipose tissue. In preclinical models, adding GCGR activity to a dual-agonist strengthened visceral-fat reduction and improved hepatic parameters in MASLD/MASH models.

The synergy of these three pathways has been reported in literature on retatrutide as producing deeper body-weight reduction and metabolic normalization than mono-agonist and dual-agonist strategies. The key reference data come from Coskun et al. (2022), Jastreboff et al. (2023) and Rosenstock et al. (2023). A direct contextual comparison with semaglutide and retatrutide is discussed in the article on mechanisms and clinical outcomes.

Position in the incretin-peptide classification

The incretin-peptide landscape can be divided into three generations according to the number of receptors activated. The table below organizes pharmacological class and regulatory status.

This distinction is regulatory and practical: mono- and dual-agonists include approved therapeutic products, while tri-agonists, including retatrutide, remain investigational. Triple G in the One Peptides catalog is supplied as a Research Use Only reagent, not as a clinical analog or a product for administration to humans. The visual similarity of a pen format to pharmaceutical pens does not change this classification.

Triple G 20 mg PEN vs Triple G 10 mg vial in the One Peptides catalog

Triple G may be discussed in two physical formats: a lyophilized vial and a pre-dissolved pen. The active class and analytical expectations remain the same; the difference concerns laboratory handling.

The preferred format depends on the protocol. A lyophilized vial gives maximum flexibility when the researcher needs to define the starting concentration or use a specific buffer. The 20 mg PEN simplifies work with a ready solution of higher nominal peptide content, which is useful in serial protocols with repeated volume sampling. Analytical quality is expected to be identical across formats. The catalog also includes the related GLP-1+GIP PEN in the dual-agonist class, useful as a comparative material.

Triple G 20 mg – applications in scientific research

Triple G 20 mg PEN is an RUO reagent for experimental work in several research directions.

Incretin-axis pharmacology. Receptor-activity analysis, selectivity profiling for GLP-1R/GIPR/GCGR, and EC50 measurement in cell-culture systems using cAMP or beta-arrestin signaling reporters.

Animal models of insulin resistance and obesity. DIO mice on high-fat diets, ob/ob and db/db models, and Zucker rat models. Typical endpoints include body weight, body composition by DEXA or NMR, OGTT/ITT, HOMA-IR and lipid profile.

MASLD/MASH models. Hepatic steatosis and fibrosis are areas where triple activation with GCGR agonism has shown particular interest compared with dual-agonist approaches. Typical readouts include liver weight, triglyceride content, ALT/AST, histology and inflammatory/fibrotic markers.

Comparative pharmacology. Direct comparison with semaglutide-like mono-agonists and tirzepatide-like dual-agonists allows researchers to separate the added contribution of the glucagon receptor pathway. This makes tri-agonist models useful in studies focused on energy expenditure, hepatic lipid metabolism and appetite regulation.

One Peptides quality specification

• HPLC >=98% – purity verified by high-performance liquid chromatography with UV detection; main-peak area >=98% of total peak area.
• MS confirmation – structural identity confirmed by mass spectrometry in the expected ~4500-4900 Da range.
• COA per batch – public certificate of analysis for each lot, including theoretical/measured mass, HPLC profile, MS spectrum, synthesis date and batch number.
• Cold chain 2-8 °C – refrigerated logistics with monitoring from synthesis to delivery.
• Batch traceability – lot number visible in three places: pen label, invoice and COA.

For more background on analytical verification and documentation, see the One Peptides page on quality testing and certificates.

Working with a pre-dissolved PEN in a laboratory protocol

The pre-dissolved pen format changes the workflow compared with a lyophilized vial. The researcher does not perform the first reconstitution step, so the risk of concentration error from solvent-volume selection is reduced. At the same time, the fixed nominal concentration means that further dilution design must be planned around the manufacturer’s starting solution.

In practice, the key steps are: visual inspection of the solution, verification of batch documentation, sterile sampling, aliquoting when required by the protocol, and storage under refrigerated conditions. If additional dilutions are needed, use validated sterile diluent systems and calculate the final working concentration carefully. The general principles are described in the guide on how to dissolve peptides and in the peptide calculator.

The pen should be treated as a laboratory reagent container, not as a clinical dosing device. It is not intended for self-administration, therapeutic dosing, bodybuilding protocols or cosmetic use.

Regulatory status – Triple G, retatrutide and GLP-1 medicines

The regulatory status of tri-agonists is often misunderstood because their terminology overlaps with approved GLP-1 medicines. Semaglutide and tirzepatide are medicines with defined indications, manufacturing standards, clinical dosing and pharmacovigilance. Retatrutide, despite strong clinical data, remains investigational. Triple G products supplied as research reagents are outside therapeutic use.

For this reason, Triple G 20 mg PEN is sold strictly as Research Use Only. It is intended for in vitro, analytical, biochemical and preclinical research contexts where permitted by local regulations. It is not a medicine, dietary supplement, food ingredient or cosmetic ingredient. See also the broader legal overview of research reagents in the European Union.

FAQ – Frequently Asked Questions

References

1. Coskun T et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
2. Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.
3. Rosenstock J et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.
4. Frias JP et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
5. Nahra R et al. (2021). Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes.